Understanding mutations in BMP receptors related to pulmonary arterial hypertension
Elucidating the structural insights into the BMP receptor mutations in PAH
This study is looking at how changes in a specific protein can affect people with pulmonary arterial hypertension (PAH) to help find new treatments for this serious condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11051891 on NIH RePORTER |
What this research studies
This research investigates how mutations in the bone morphogenetic protein receptor type 2 (BMPR2) contribute to pulmonary arterial hypertension (PAH), a severe condition that can lead to heart failure. The study aims to uncover the structural and functional aspects of these mutations to better understand their role in the disease. By examining the receptor's signaling pathways and how they are affected by these mutations, the research seeks to identify potential new therapies for patients with PAH. The approach includes detailed molecular modeling and analysis of receptor interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those with known BMPR2 mutations.
Not a fit: Patients without pulmonary arterial hypertension or those whose condition is not linked to BMPR2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with pulmonary arterial hypertension caused by BMPR2 mutations.
How similar studies have performed: Previous research has shown promise in understanding BMP receptor signaling, but this specific investigation into BMPR2 mutations is novel and aims to fill critical gaps in current knowledge.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hata, Akiko — University of California, San Francisco
- Study coordinator: Hata, Akiko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.